P4HA2 involved in SLUG-associated EMT predicts poor prognosis of patients with KRAS-positive colorectal cancer
Medical Molecular Morphology · 2024-09 · 57 (3) · 167-176
DOI: 10.1007/s00795-024-00385-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Molecular Morphology, online erschienen am 24.03.2024. Verfasst von Heba El-Deek Mohammed El-Deek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt. Hebaeldeek@gmail.com. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Colorectal Neoplasms, Epithelial-Mesenchymal Transition, Mutation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Assiut University.
Abstract (Originalsprache)
This study aimed to examine the immunohistochemical expression of epithelial–mesenchymal transition biomarkers: P4HA2 and SLUG in colorectal carcinoma (CRC) specimens, then to assess their relation to clinicopathological features including KRAS mutations and patients’ survival, and finally to study the correlation between them in CRC. The result of this study showed that SLUG and P4HA2 were significantly higher in association with adverse prognostic factors: presence of lympho-vascular invasion, perineural invasion, higher tumor budding, tumor stage, presence of lymph node metastasis, and presence of distant metastasis. CRC specimens with KRAS mutation were associated with significant higher SLUG and P4HA2 expression. High expression of both SLUG and P4HA2 was significantly unfavorable prognostic indicator as regards overall survival (OS) and disease-free survival (DFS). In KRAS mutated cases, high P4HA2 expression was the only significant poor prognostic indicator as regarding DFS. In conclusions, our data highlight that both SLUG and P4HA2 expression may serve as potentially important poor prognostic biomarkers in CRC and targeting these molecules may be providing a novel therapeutic strategy. In KRAS mutation group, high P4HA2 expression is the only independent prognostic factor for tumor recurrence, so it can be suggested to be a novel target for therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt. Hebaeldeek@gmail.com.
- Department of Clinical Oncology, Faculty of Medicine, Assiut University Hospital, Assiut, Egypt.
- Department of Medical Oncology and Hematological Malignancies, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
- Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, South Valley University, Qena, Egypt.
- Department of Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Förderung
- Assiut University
Zitieren
APA
El-Deek, H. E. M., El-Naggar, M. S., Morsy, A. M. M., Sedik, M. F., Osman, H. A., & Ahmed, A. M. (2024). P4HA2 involved in SLUG-associated EMT predicts poor prognosis of patients with KRAS-positive colorectal cancer. Medical Molecular Morphology, 57(3), 167-176. https://doi.org/10.1007/s00795-024-00385-0
Vancouver
El-Deek HEM, El-Naggar MS, Morsy AMM, Sedik MF, Osman HA, Ahmed AM. P4HA2 involved in SLUG-associated EMT predicts poor prognosis of patients with KRAS-positive colorectal cancer. Medical Molecular Morphology. 2024;57(3):167-176. doi:10.1007/s00795-024-00385-0
BibTeX
@article{ElDeek2024,
author = {El-Deek, Heba El-Deek Mohammed and El-Naggar, Maha Salah and Morsy, Aiat Morsy Mohamed and Sedik, Mayada Fawzy and Osman, Heba Ahmed and Ahmed, Asmaa M},
title = {P4HA2 involved in SLUG-associated EMT predicts poor prognosis of patients with KRAS-positive colorectal cancer},
journal = {Medical Molecular Morphology},
year = {2024},
volume = {57},
number = {3},
pages = {167--176},
doi = {10.1007/s00795-024-00385-0}
}
EUVIMED